STUDY TYPE

Evaluating equivalence of MSB11456 (Tocilizumab proposed Biosimilar) with the Tocilizumab that is used both the USA and in European Union.

STUDY DESCRIPTION

Randomised, Double- Blind Single Dose Study to evaluate equivalence of MSB11456 (Tocilizumab proposed Biosimilar) with the Tocilizumab that is used both the USA and in European Union.

STUDY AIMS

To see if the body absorbs, distributes, and gets rid of MSB11456 in the same way as the USA and European Union approved Tocilizumab, and to assess the safety of MSB11456.

CANDIDATES

Gender: Male and Female
Age: 18 to 55 Years

IMPORTANT DOCUMENTS

Content and Information: Download the full file here.
Visit Planners:
 Download the Simba Visit Planner

FURTHER INFORMATION

Please note study participants need to be over 60kg.

CCST needs people to participate in our clinical research

CCST provides world class research facilities and expertise